NCT03324425View on ClinicalTrials.gov

Simvastatin Plus Dual Anti-HER2 Therapy for Metastatic Breast Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

March 4, 2020

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2030

Conditions
Breast Cancer Stage IV
Interventions
DRUG

Simvastatin 80mg

Participants will receive simvastatin 80 mg by mouth daily at bedtime

Trial Locations (2)

77054

Harris Health System - Smith Clinic, Houston

O'Quinn Medical Tower - McNair Campus; Dan L Duncan Comprehensive Cancer Center, Houston

All Listed Sponsors
lead

Baylor Breast Care Center

OTHER